PE20020576A1 - DRUG COMPOSITIONS BASED ON ANTICHOLINERGIC AND CORTICOSTEROID AGENTS - Google Patents
DRUG COMPOSITIONS BASED ON ANTICHOLINERGIC AND CORTICOSTEROID AGENTSInfo
- Publication number
- PE20020576A1 PE20020576A1 PE2001001073A PE2001001073A PE20020576A1 PE 20020576 A1 PE20020576 A1 PE 20020576A1 PE 2001001073 A PE2001001073 A PE 2001001073A PE 2001001073 A PE2001001073 A PE 2001001073A PE 20020576 A1 PE20020576 A1 PE 20020576A1
- Authority
- PE
- Peru
- Prior art keywords
- agents
- holyphole
- hiphole
- sulphonate
- vitamin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000812 cholinergic antagonist Substances 0.000 title abstract 2
- 239000003470 adrenal cortex hormone Substances 0.000 title 1
- 230000001078 anti-cholinergic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- -1 CYCLESONIDE Chemical compound 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 abstract 2
- 239000011782 vitamin Substances 0.000 abstract 2
- 229930003231 vitamin Natural products 0.000 abstract 2
- 235000013343 vitamin Nutrition 0.000 abstract 2
- 229940088594 vitamin Drugs 0.000 abstract 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 229960004495 beclometasone Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960000676 flunisolide Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000001282 iso-butane Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 229960001664 mometasone Drugs 0.000 abstract 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 abstract 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 abstract 1
- 229950004432 rofleponide Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000019149 tocopherols Nutrition 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN MEDICAMENTO QUE COMPRENDE 1)AGENTES ANTICOLINERGICOS COMO TIOTROPIO, OXITROPIO, IPRATROPIO SUS SALES COMO CLORURO, BROMURO, YODURO, METANO-SULFONATO, SULFATO, PARATOLUENO-SULFONATO; 2)ESTEROIDES COMO FLUNISOLIDA, BECLOMETASONA, TRIAMCINOLONA, BUDESONIDA, FLUTICASONA, MOMETASONA, CICLESONIDA, ROFLEPONIDA, DEXAMETASONA; SIENDO LA RELACION DE 1 Y 2 DE1:300 A 50:1; UTILIZANDOSE DE 0,01µg A 10000µg; SIENDO LA FORMA DE PRESENTACION a)POLVOS PARA INHALACION QUE ADEMAS CONTIENE MEZCLAS CON SUSTANCIAS AUXILIARES FISIOLOGICAMENTE INOCUAS COMO MONOSACARIDOS, DISACARIDOS, OLIGO O POLISACARIDOS, POLIALCOHOLES CARACTERIZADA POR SU TAMANO DE PARTICULAS DE HASTA 250µm, b)AEROSOLES DOSIFICABLES CON UN CONTENIDO DE GAS PROPULSOR (n-PROPANO, n-BUTANO, ISOBUTANO, ENTRE OTROS) QUE CONTIENE LAS SUSTANCIAS ACTIVAS EN FORMA DISUELTA O DISPERSA Y c)SOLUCIONES O SUSPENSIONES PARA INHALACION EXENTAS DE GAS PROPULSOR QUE CONTIENE COMO DISOLVENTE AGUA, ETANOL; CODISOLVENTES COMO ALCOHOL ISOPROPILICO, GLICOLES, POLIOXIETILEN ALCOHOLES; AGENTE FORMADOR DE COMPLEJO COMO ACIDO ETIDINICO; AGENTES ANTIOXIDANTES COMO ACIDO ASCORBICO, VITAMINA A, VITAMINA E, TOCOFEROLES; AGENTES DE CONSERVACION COMO CETIL PIRIDINIO, CLORURO DE BENZALCONIO CON UN pH DE 2-7 QUE SE AJUSTA ADICIONANDO ACIDO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIASIT REFERS TO A MEDICINAL PRODUCT THAT INCLUDES 1) ANTICHOLINERGIC AGENTS SUCH AS THYOTROPE, OXITROPE, IPRATROPE, ITS SALTS SUCH AS CHLORIDE, BROMIDE, IODIDE, METHANE-SULPHONATE, SULPHATE, PARATOLUENE-SULPHONATE; 2) STEROIDS LIKE FLUNISOLIDE, BECLOMETASONE, TRIAMCINOLONE, BUDESONIDE, FLUTICASONE, MOMETASONE, CYCLESONIDE, ROFLEPONIDE, DEXAMETASONE; BEING THE RATIO OF 1 AND 2 FROM 1: 300 TO 50: 1; USING FROM 0.01µg TO 10000µg; BEING THE FORM OF PRESENTATION a) INHALATION POWDERS THAT ALSO CONTAIN MIXTURES WITH PHYSIOLOGICALLY HARMFUL AUXILIARY SUBSTANCES SUCH AS MONOSACCHARIDS, DISACCHARIDES, OLIGO OR POLYSACCHARIDES, POLYALCOHOLS CHARACTERIZED BY ITS SIZE OF PARTICULAR HOLYPHOLE HOLYPHOLE GULF 250 µS, CONTAINED BY ITS SIZE OF HIPHOLE HIPHOLE GOLM. n-PROPANE, n-BUTANE, ISOBUTANE, AMONG OTHERS) CONTAINING THE ACTIVE SUBSTANCES IN DISSOLVED OR DISPERSED FORM AND c) SOLUTIONS OR SUSPENSIONS FOR INHALATION FREE FROM PROPULSOR GAS CONTAINING ETHANOL AS A SOLVENT WATER; CODISOLVENTS SUCH AS ISOPROPYL ALCOHOL, GLYCOLS, POLYOXYETHYLENE ALCOHOLS; COMPLEX FORMING AGENT LIKE ETIDINIC ACID; ANTIOXIDANT AGENTS LIKE ASCORBIC ACID, VITAMIN A, VITAMIN E, TOCOPHEROLS; PRESERVATION AGENTS SUCH AS CETIL PYRIDINIUM, BENZALCONIUM CHLORIDE WITH A pH OF 2-7 THAT IS ADJUSTED BY ADDING ACID. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE RESPIRATORY TRACT
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10054042 | 2000-10-31 | ||
DE10062712A DE10062712A1 (en) | 2000-12-15 | 2000-12-15 | New drug compositions based on anticholinergics and corticosteroids |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020576A1 true PE20020576A1 (en) | 2002-08-09 |
Family
ID=26007540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001001073A PE20020576A1 (en) | 2000-10-31 | 2001-10-29 | DRUG COMPOSITIONS BASED ON ANTICHOLINERGIC AND CORTICOSTEROID AGENTS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1333830A2 (en) |
JP (1) | JP2004512359A (en) |
AU (1) | AU2002210575A1 (en) |
CA (2) | CA2436540C (en) |
MX (1) | MXPA03003751A (en) |
PE (1) | PE20020576A1 (en) |
UY (1) | UY26992A1 (en) |
WO (1) | WO2002036106A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US7311894B2 (en) | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
DE10214263A1 (en) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA suspension formulations containing an anticholinergic |
US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
US7084153B2 (en) | 2002-04-12 | 2006-08-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising steroids and a novel anticholinergic |
DE10216429A1 (en) * | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Synergistic medicaments for treating inflammatory or obstructive respiratory tract diseases, containing quaternized scopine ester anticholinergic agent and steroid, e.g. budesonide |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US20040102469A1 (en) * | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
DE602005022499D1 (en) | 2004-05-31 | 2010-09-02 | Almirall Sa | Combinations with antimuscarinic agents and PDE4 inhibitors |
ES2257152B1 (en) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
EP1763344A1 (en) * | 2004-06-29 | 2007-03-21 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising steroids and an anticholinergic |
GB0523653D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
ES2298049B1 (en) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO. |
EP2327403A3 (en) | 2007-02-19 | 2011-08-31 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators |
EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
TR200909792A2 (en) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Dry powder combination containing tiotropium, corticosteroid and a combination of chromoglycic acid derivative |
TR200909793A2 (en) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Combination of dry powder containing a combination of tiotropium, mometasone and a chromoglycic acid derivative. |
TR200909789A2 (en) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Dry powder combination containing tiotropium, budesonide and a chromoglycic acid derivative combination |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
AU2021314977A1 (en) | 2020-07-31 | 2023-03-02 | Chemo Research, S.L. | Combination therapy for inhalation administration |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE19835346A1 (en) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Two-part capsule for pharmaceutical preparations for powder inhalers |
GB0009605D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
GB0009592D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
-
2001
- 2001-10-23 WO PCT/EP2001/012511 patent/WO2002036106A2/en active Application Filing
- 2001-10-23 CA CA002436540A patent/CA2436540C/en not_active Expired - Fee Related
- 2001-10-23 AU AU2002210575A patent/AU2002210575A1/en not_active Abandoned
- 2001-10-23 MX MXPA03003751A patent/MXPA03003751A/en active IP Right Grant
- 2001-10-23 JP JP2002538918A patent/JP2004512359A/en active Pending
- 2001-10-23 EP EP01978463A patent/EP1333830A2/en not_active Ceased
- 2001-10-23 CA CA2733294A patent/CA2733294C/en not_active Expired - Fee Related
- 2001-10-29 PE PE2001001073A patent/PE20020576A1/en not_active Application Discontinuation
- 2001-10-29 UY UY26992A patent/UY26992A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2436540A1 (en) | 2002-05-10 |
CA2733294A1 (en) | 2002-05-10 |
JP2004512359A (en) | 2004-04-22 |
WO2002036106A2 (en) | 2002-05-10 |
CA2733294C (en) | 2011-12-20 |
MXPA03003751A (en) | 2004-10-15 |
WO2002036106A3 (en) | 2002-09-19 |
CA2436540C (en) | 2008-01-29 |
AU2002210575A1 (en) | 2002-05-15 |
UY26992A1 (en) | 2002-06-20 |
EP1333830A2 (en) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020576A1 (en) | DRUG COMPOSITIONS BASED ON ANTICHOLINERGIC AND CORTICOSTEROID AGENTS | |
US11219631B2 (en) | Foamable compositions, breakable foams and their uses | |
US10946101B2 (en) | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | |
US10350166B2 (en) | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses | |
JP2007106777A (en) | Topical nasal treatment | |
JP2008540508A (en) | Foaming vehicle and pharmaceutical composition thereof | |
EP0630229B1 (en) | Pressurized gas packagings using polyoxyethylene glyceryl-obates | |
EP0633019B1 (en) | Pressurized gas packagings using polyoxyethylene glyceryl fatty acid esters as suspension stabilizers and valve lubricants | |
BR132017012408E2 (en) | COMPOUND, PROCESS FOR PREPARING A COMPOUND, STABLE TOPIC PHARMACEUTICAL COMPOSITIONS OF HALOBETASOL | |
CN101951886A (en) | Enhancing photostabilization of oxymetazoline | |
PE20040326A1 (en) | MEDICINE CONTAINING STEROIDS AND A NEW ANTICHOLINERGIC | |
RU2006105719A (en) | COMBINATION FROM ANTICHOLINERGIC AGENT AND STEROID AND ITS APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES BY INHALATION | |
PE20030092A1 (en) | FORMULATION OF AN INHALATION SOLUTION WITH A TIOTROPE SALT | |
US11642309B2 (en) | Aqueous compositions comprising bilastine and mometasone | |
EP1670464A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
AU2015224534B2 (en) | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | |
JPH04149131A (en) | Indomethactin liquid for external use | |
JPS63132838A (en) | Drug composition for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |